$10.06▴ 5.45%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-32.07MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Immix Biopharma, Inc. is pre-profit. It is still burning cash while pre-profit.
Key numbers
Valuation
EPS (TTM)$-0.92
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$0.00
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days4 articles
0 bullish0 neutral4 bearish
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
EQPT LAWSUIT: EquipmentShare.com Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton To Learn How They Might Recover Their Losses
Immix Biopharma Investigated by the Portnoy Law Firm
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.